Operating CF
$5.01B
Capex
-$858M
Free Cash Flow
$4.16B
FCF Margin
+82.9%
Cash flow waterfall for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
Free cash flow: $4.16B
Cash flow breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $5.01B | $5.01B |
| Capital Expenditure | -$858M | $4.16B |
| Free Cash Flow | $4.16B | $4.16B |
| Other Investing | -$848M | $3.31B |
| Share Buybacks | -$3.19B | $116M |
| Dividends Paid | -$374M | -$259M |
| Other Financing & FX | $136M | -$122M |
| Net Cash Decrease | -$122M | -$122M |
- Operating Cash Flow$5.01B
- Capital Expenditure-$858M
- Free Cash Flow$4.16B
- Other Investing-$848M
- Share Buybacks-$3.19B
- Dividends Paid-$374M
- Other Financing & FX$136M
- Net Cash Decrease-$122M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.